Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant  or a left ventricular assist device (LVAD).

COVID-19 disrupted all aspects of science and medicine and unmasked striking disparities and opportunities for transformation. Coronavirus impact this past year is expected to result in a massive rise in new cases of chronic health conditions, including cardiolvascular disease and heart failure.
News | Coronavirus (COVID-19) | April 07, 2021
April 6, 2021 — A tsunami of chronic health conditions as a result of the COVID-19 (SARS-CoV-2) pandemic, especially...
The Transmedics Organ Care System (OCS) Heart, or “Heart in a Box,” enables transplant surgeons to travel to much farther destinations to procure transplant hearts by acting as a miniature intensive care unit that keeps the heart alive.

The Transmedics Organ Care System (OCS) Heart, or “Heart in a Box,” enables transplant surgeons to travel to much farther destinations to procure transplant hearts by acting as a miniature intensive care unit that keeps the heart alive.

News | Cardiovascular Surgery | April 05, 2021
April 5, 2021 — Smidt Heart Institute transplant surgeons Dominic Emerson, M.D., and Pedro Catarino, M.D. know how to...
PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

News | Heart Failure | March 24, 2021
March 24, 2021 — Endotronix Inc., a digital health and medical technology company working on advancements in treating...
Videos | Ventricular Assist Devices (VAD) | March 22, 2021
Surgeons at Penn State Heart and Vascular Institute were the second group in the nation to implant a newly-designed...
A study from Washington University School of Medicine in St. Louis provides evidence that the coronavirus can invade and replicate inside heart muscle cells, causing cell death and interfering with heart muscle contraction. The image of engineered heart tissue shows human heart muscle cells (red) infected with COVID-19 (SARS-CoV-2) (green). Image by Lina Greenberg.

A study from Washington University School of Medicine in St. Louis provides evidence that the coronavirus can invade and replicate inside heart muscle cells, causing cell death and interfering with heart muscle contraction. The image of engineered heart tissue shows human heart muscle cells (red) infected with COVID-19 (SARS-CoV-2) (green). Image by Lina Greenberg.

Feature | Coronavirus (COVID-19) | March 12, 2021
March 12, 2021 — Since early in the pandemic, COVID-19 has been associated with heart problems, including reduced...
AMERICAN COLLEGE OF CARDIOLOGY (ACC) Late-breaking clinical trial study presentations at ACC.21. @ACC21 @ACC2021
Feature | ACC | March 08, 2021 | Dave Fornell, Editor
The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announced...
News | Cardiac Resynchronization Therapy Devices (CRT) | March 03, 2021
March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac...
Impulse Dynamics Optimizer Smart device is an implantable device that helps optimize cardiac pumping action in heart failure patients.

Impulse Dynamics Optimizer Smart device is an implantable device that helps optimize cardiac pumping action in heart failure patients.

News | Heart Failure | March 03, 2021
March 3, 2021 — Impulse Dynamics recently announced that DEKRA Certification B.V., a global regulatory organization,...
LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

News | Heart Failure | March 02, 2021
March 2, 2021 — Penn State Health Milton S. Hershey Medical Center became the second hospital in the nation to implant...
Medtronic Recalls HVAD Pump Implant Kits After 2 Deaths and 19 Serious Injuries
News | Ventricular Assist Devices (VAD) | March 01, 2021
March 1, 2021 — Medtronic is recalling the HeartWare Ventricular Assist Device (HVAD) Pump Implant Kit because the left...
The Occlutech implantable Atrial Flow Regulator (AFR) maintains an interatrial shunt with a predetermined diameter allowing for controlled blood flow from the left to the right atrium enabling the left atrium to decompress and lower left atrial pressure. This reduced left atrial pressure reduces heart failure symptoms and improves exercise tolerance.
News | Heart Failure | February 24, 2021
February 24, 2021 — Occlutech announced the completion of patient enrollment in the PRELIEVE trial, pilot study to...
The Occlutech implantable Atrial Flow Regulator (AFR) maintains an interatrial shunt with a predetermined diameter allowing for controlled blood flow from the left to the right atrium enabling the left atrium to decompress and lower left atrial pressure. This reduced left atrial pressure reduces heart failure symptoms and improves exercise tolerance.

The Occlutech implantable Atrial Flow Regulator (AFR) maintains an interatrial shunt with a predetermined diameter allowing for controlled blood flow from the left to the right atrium enabling the left atrium to decompress and lower left atrial pressure. This reduced left atrial pressure reduces heart failure symptoms and improves exercise tolerance.
 

News | Heart Failure | January 27, 2021
January, 27, 2021 — The U.S. Food and Drug Administration (FDA) has granted Occlutech a Breakthrough Device designation...
FDA clears Verquvo, Vericiguat, Heart failure drug.
News | Heart Failure | January 25, 2021
January 25, 2021 — The U.S. Food and Drug Administration (FDA) approved Merck's Verquvo (vericiguat). It is the first...
The FineHeart Transcutaneous Energy Transfer (TET) System for the ICOMS cardiac assist device. 1. The ICOMS heart pump. 2. The implanted TET transfer pad. 3. The external energy transfer pad.

The FineHeart Transcutaneous Energy Transfer (TET) System for the ICOMS cardiac assist device. 1. The ICOMS heart pump. 2. The implanted TET transfer pad. 3. The external energy transfer pad.

News | Heart Failure | January 13, 2021
January 13, 2021 — FineHeart, a preclinical-stage medical device company developing a novel left ventricular assist...
Coffee and tea are good for your heart, heart healthy. Top News Stories in 2020 From the European Society of Cardiology
News | December 29, 2020
December 29, 2020 — Here is a list of the top 10 news stories from the European Society of Cardiology (ESC) in 2020...